Entellus Medical Company Profile (NASDAQ:ENTL)

About Entellus Medical (NASDAQ:ENTL)

Entellus Medical logoEntellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENTL
  • CUSIP: N/A
  • Web: www.entellusmedical.com
Capitalization:
  • Market Cap: $342.77 million
  • Outstanding Shares: 21,916,000
Average Prices:
  • 50 Day Moving Avg: $13.50
  • 200 Day Moving Avg: $15.48
  • 52 Week Range: $11.47 - $22.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.77
  • P/E Growth: -0.56
Sales & Book Value:
  • Annual Revenue: $77.39 million
  • Price / Sales: 4.43
  • Book Value: $3.42 per share
  • Price / Book: 4.57
Profitability:
  • EBIDTA: ($25,430,000.00)
  • Net Margins: -39.02%
  • Return on Equity: -60.56%
  • Return on Assets: -35.90%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 4.57%
  • Quick Ratio: 4.21%
Misc:
  • Average Volume: 169,988 shs.
  • Beta: 0.04
  • Short Ratio: 6.61
 

Frequently Asked Questions for Entellus Medical (NASDAQ:ENTL)

What is Entellus Medical's stock symbol?

Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."

How were Entellus Medical's earnings last quarter?

Entellus Medical, Inc. (NASDAQ:ENTL) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The firm had revenue of $19.11 million for the quarter, compared to the consensus estimate of $19.61 million. Entellus Medical had a negative net margin of 39.02% and a negative return on equity of 60.56%. The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.37) EPS. View Entellus Medical's Earnings History.

When will Entellus Medical make its next earnings announcement?

Entellus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Entellus Medical.

Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?

7 brokerages have issued 1 year price targets for Entellus Medical's shares. Their forecasts range from $16.00 to $26.00. On average, they expect Entellus Medical's share price to reach $22.00 in the next year. View Analyst Ratings for Entellus Medical.

What are analysts saying about Entellus Medical stock?

Here are some recent quotes from research analysts about Entellus Medical stock:

  • 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (5/9/2017)
  • 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)

Who are some of Entellus Medical's key competitors?

Who are Entellus Medical's key executives?

Entellus Medical's management team includes the folowing people:

  • Robert S. White, President, Chief Executive Officer, Director
  • Brent A. Moen, Chief Financial Officer, Corporate Secretary
  • Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel
  • Stephen R. Paidosh, Vice President, Operations
  • Thomas D. Williamson, Vice President - Sales
  • Kevin L. Mensink, Vice President of Marketing
  • Martha J. Christian, Vice President, Reimbursement
  • Timothy B. Petrick, Vice President, Research and Development
  • Brian E. Farley, Non-Executive Chairman of the Board
  • John K. Bakewell, Independent Director

When did Entellus Medical IPO?

(ENTL) raised $70 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Entellus Medical stock?

Entellus Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SV Health Investors LLC (13.51%), DISCOVERY GROUP I, LLC (9.60%), FMR LLC (2.73%), Frontier Capital Management Co. LLC (2.24%), Kingdon Capital Management L.L.C. (2.05%) and Vanguard Group Inc. (2.04%). Company insiders that own Entellus Medical stock include Brent Moen, Brian E Farley, James D Surek, Joshua J Baltzell, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano, Robert S White and Timothy B Petrick. View Institutional Ownership Trends for Entellus Medical.

Who sold Entellus Medical stock? Who is selling Entellus Medical stock?

Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including SV Health Investors LLC, FMR LLC, Renaissance Technologies LLC, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick. View Insider Buying and Selling for Entellus Medical.

Who bought Entellus Medical stock? Who is buying Entellus Medical stock?

Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, William Blair Investment Management LLC, Kingdon Capital Management L.L.C., Grandeur Peak Global Advisors LLC, Vanguard Group Inc., Laurion Capital Management LP, Royce & Associates LP and Blair William & Co. IL. Company insiders that have bought Entellus Medical stock in the last two years include Brent Moen, Joshua J Baltzell and Robert S White. View Insider Buying and Selling for Entellus Medical.

How do I buy Entellus Medical stock?

Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Entellus Medical's stock price today?

One share of Entellus Medical stock can currently be purchased for approximately $15.64.


MarketBeat Community Rating for Entellus Medical (NASDAQ ENTL)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Entellus Medical (NASDAQ:ENTL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $22.00 (40.66% upside)

Analysts' Ratings History for Entellus Medical (NASDAQ:ENTL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Canaccord GenuitySet Price TargetHold$18.00LowView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
2/22/2017Bank of America CorporationDowngradeBuy -> Underperform$16.00N/AView Rating Details
2/22/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
12/14/2016Piper Jaffray CompaniesReiterated RatingPositiveN/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$25.00N/AView Rating Details
11/4/2016Deutsche Bank AGReiterated RatingBuy$25.00 -> $26.00N/AView Rating Details
(Data available from 6/26/2015 forward)

Earnings

Earnings History for Entellus Medical (NASDAQ:ENTL)
Earnings by Quarter for Entellus Medical (NASDAQ:ENTL)
Earnings History by Quarter for Entellus Medical (NASDAQ ENTL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/3/2017Q1 2017($0.44)($0.40)$19.61 million$19.11 millionViewListenView Earnings Details
2/21/2017Q4 2016($0.33)($0.39)$21.58 million$21.70 millionViewListenView Earnings Details
11/3/2016Q3($0.37)($0.50)$17.93 million$17.90 millionViewListenView Earnings Details
8/3/2016Q2($0.35)($0.27)$18.48 million$18.73 millionViewListenView Earnings Details
5/4/2016Q1($0.47)($0.37)$16.34 million$16.90 millionViewListenView Earnings Details
2/24/2016Q4($0.26)($0.27)$17.52 million$18.07 millionViewListenView Earnings Details
11/5/2015Q315($0.25)($0.32)$14.19 million$14.80 millionViewListenView Earnings Details
8/6/2015Q215($0.20)($0.15)$15.00 million$15.20 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Entellus Medical (NASDAQ:ENTL)
2017 EPS Consensus Estimate: ($1.35)
2018 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171($0.26)($0.26)($0.26)
Q1 20181($0.32)($0.32)($0.32)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Entellus Medical (NASDAQ:ENTL)
Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 75.79%
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/8/2017Brent MoenCFOBuy6,100$12.21$74,481.00View SEC Filing  
5/8/2017Joshua J BaltzellDirectorBuy1,600$12.34$19,744.00View SEC Filing  
5/8/2017Robert S. WhiteInsiderBuy10,000$12.24$122,400.00View SEC Filing  
1/31/2017Life Sciences Fu InternationalMajor ShareholderSell533,077$17.00$9,062,309.00View SEC Filing  
1/13/2017Brian E FarleyDirectorSell14,019$20.14$282,342.66View SEC Filing  
1/13/2017Karen E. PetersonVPSell10,000$20.13$201,300.00View SEC Filing  
1/10/2017Brian E FarleyDirectorSell9,842$19.11$188,080.62View SEC Filing  
1/10/2017Karen E. PetersonVPSell9,840$19.11$188,042.40View SEC Filing  
1/4/2017Brian E FarleyDirectorSell20,158$18.74$377,760.92View SEC Filing  
1/4/2017Karen E PetersonVPSell10,160$18.74$190,398.40View SEC Filing  
12/6/2016Brian E FarleyDirectorSell15,000$18.57$278,550.00View SEC Filing  
11/23/2016Brian E FarleyDirectorSell5,000$19.00$95,000.00View SEC Filing  
11/18/2016Brian E FarleyDirectorSell10,000$18.30$183,000.00View SEC Filing  
10/13/2016Margaret A. BoianoVPSell11,103$20.01$222,171.03View SEC Filing  
10/5/2016Brian E FarleyDirectorSell30,000$22.26$667,800.00View SEC Filing  
9/8/2016James D SurekVPSell10,000$18.71$187,100.00View SEC Filing  
9/2/2016Brian E FarleyDirectorSell11,078$18.62$206,272.36View SEC Filing  
9/1/2016Brian E FarleyDirectorSell17,006$19.33$328,725.98View SEC Filing  
9/1/2016Kevin L. MensinkVPSell8,000$18.39$147,120.00View SEC Filing  
8/1/2016Kevin L MensinkVPSell8,100$17.63$142,803.00View SEC Filing  
7/18/2016Timothy B. PetrickVPSell3,000$18.15$54,450.00View SEC Filing  
2/11/2016Karen E PetersonInsiderSell5,000$16.00$80,000.00View SEC Filing  
2/4/2016Karen E PetersonInsiderSell10,000$17.00$170,000.00View SEC Filing  
9/17/2015Brian E. FarleyChairmanSell5,484$22.00$120,648.00View SEC Filing  
9/15/2015Brian E. FarleyChairmanSell27,619$22.18$612,589.42View SEC Filing  
9/14/2015Brian E. FarleyChairmanSell21,187$22.15$469,292.05View SEC Filing  
9/2/2015James D SurekVPSell15,000$21.27$319,050.00View SEC Filing  
8/31/2015James D. SurekVPSell5,000$22.29$111,450.00View SEC Filing  
2/3/2015Robert S WhiteCOOBuy5,882$17.00$99,994.00View SEC Filing  
2/3/2015Shawn MccormickDirectorBuy2,941$17.00$49,997.00View SEC Filing  
2/3/2015Woodlands Health Venture EssexMajor ShareholderBuy352,941$17.00$5,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Entellus Medical (NASDAQ:ENTL)
Latest Headlines for Entellus Medical (NASDAQ:ENTL)
Source:
DateHeadline
americanbankingnews.com logo Analysts Expect Entellus Medical, Inc. (ENTL) Will Post Quarterly Sales of $21.17 Million
www.americanbankingnews.com - June 23 at 4:00 PM
americanbankingnews.com logoZacks: Analysts Anticipate Entellus Medical, Inc. (ENTL) to Announce -$0.34 EPS
www.americanbankingnews.com - June 21 at 12:08 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 5:59 PM
finance.yahoo.com logoEntellus Medical, Inc. :ENTL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 5:24 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM
finance.yahoo.com logoEntellus Medical to Present at the William Blair Growth Stock Conference
finance.yahoo.com - June 1 at 5:45 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 8:00 AM
americanbankingnews.com logo$21.17 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 28 at 9:54 AM
americanbankingnews.com logo-$0.34 Earnings Per Share Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 26 at 8:54 AM
americanbankingnews.com logoCanaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target
www.americanbankingnews.com - May 23 at 9:20 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM
finance.yahoo.com logoThe Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation
finance.yahoo.com - May 22 at 4:43 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 12 at 10:20 AM
americanbankingnews.com logoQ2 2018 Earnings Forecast for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 11 at 2:14 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Earns "Outperform" Rating from William Blair
www.americanbankingnews.com - May 10 at 3:26 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:38 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Director Buys $19,744.00 in Stock
www.americanbankingnews.com - May 8 at 10:08 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Insider Acquires $122,400.00 in Stock
www.americanbankingnews.com - May 8 at 8:23 PM
americanbankingnews.com logoBrent Moen Acquires 6,100 Shares of Entellus Medical Inc (ENTL) Stock
www.americanbankingnews.com - May 8 at 8:22 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Rating Lowered to Hold at Canaccord Genuity
www.americanbankingnews.com - May 7 at 12:26 PM
finance.yahoo.com logoInvestor Network: Entellus Medical, Inc. to Host Earnings Call
finance.yahoo.com - May 5 at 3:11 AM
nasdaq.com logoMid-Day Market Update: Crude Oil Down 4%; Insight Enterprises Shares Surge After Strong Q1 Results
www.nasdaq.com - May 4 at 5:08 PM
finance.yahoo.com logoHere's Why Entellus Medical Inc. Stock Is Under the Weather Today
finance.yahoo.com - May 4 at 5:08 PM
fool.com logoHere's Why Entellus Medical Inc. Stock Is Under the Weather Today
www.fool.com - May 4 at 2:41 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 3 at 7:40 PM
marketbeat.com logoEntellus reports 1Q loss
marketbeat.com - May 3 at 6:05 PM
finance.yahoo.com logoEntellus Medical Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 4:51 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 3 at 8:42 AM
americanbankingnews.com logoEntellus Medical (ENTL) Given News Impact Score of 0.31
www.americanbankingnews.com - May 2 at 6:38 PM
americanbankingnews.com logoEntellus Medical (ENTL) Getting Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 28 at 2:00 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 7:53 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Short Interest Update
www.americanbankingnews.com - April 24 at 5:54 PM
finance.yahoo.com logoEntellus Medical, Inc. – Value Analysis (NASDAQ:ENTL) : April 24, 2017
finance.yahoo.com - April 24 at 4:49 PM
americanbankingnews.com logoEntellus Medical (ENTL) Earns Daily Coverage Optimism Rating of 0.12
www.americanbankingnews.com - April 24 at 10:44 AM
americanbankingnews.com logoEntellus Medical (ENTL) Earning Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 2:40 PM
finance.yahoo.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : April 21, 2017
finance.yahoo.com - April 21 at 11:59 AM
finance.yahoo.com logoEntellus Medical to Present at the Deutsche Bank Annual Health Care Conference
finance.yahoo.com - April 20 at 5:06 PM
benzinga.com logoEntellus Medical to Report First Quarter 2017...
www.benzinga.com - April 19 at 9:57 PM
finance.yahoo.com logoEntellus Medical to Report First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 19 at 9:57 PM
americanbankingnews.com logoEntellus Medical (ENTL) Getting Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 18 at 4:06 PM
americanbankingnews.com logoEntellus Medical (ENTL) Given Daily News Impact Score of 0.28
www.americanbankingnews.com - April 15 at 9:45 AM
americanbankingnews.com logo$19.47 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - April 13 at 11:31 AM
americanbankingnews.com logoCanaccord Genuity Reiterates Buy Rating for Entellus Medical Inc (ENTL)
www.americanbankingnews.com - April 12 at 9:32 PM
finance.yahoo.com logoEntellus Medical Receives FDA 510(k) Clearance for Eustachian Tube Indication
finance.yahoo.com - April 12 at 5:01 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 7 at 9:05 PM
finance.yahoo.com logoETFs with exposure to Entellus Medical, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:38 AM
finance.yahoo.com logoEntellus Medical, Inc. (ENTL)
finance.yahoo.com - March 29 at 11:34 AM
americanbankingnews.com logoEntellus Medical Inc (ENTL) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 28 at 8:08 AM

Social

Chart

Entellus Medical (ENTL) Chart for Monday, June, 26, 2017

This page was last updated on 6/26/2017 by MarketBeat.com Staff